Anebulo Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $28.76K
- P/E (TTM)
- –
- Dividend yield
- –
About Anebulo Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication in adults. Its lead product candidate, selonabant, is a small molecule antagonist of cannabinoid receptor type-1 designed to rapidly reverse the symptoms of cannabis toxicity and reduce recovery time. The company targets emergency department patients, particularly pediatric cases suffering from accidental ingestion as well as adult cases.
The company operates in the United States and has conducted clinical study activities in the Netherlands. Its research and development efforts involve oral formulations alongside an intravenous formulation prioritized for pediatric care. Anebulo Pharmaceuticals maintains its principal executive offices in Lakeway, Texas.
Summary of the business section of Anebulo Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Anebulo Pharmaceuticals, Inc.
- Headquarters
- Lakeway, TX
- Address
- C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107 78734
- Phone
- (737) 203-5270
- Employees
- 2, Jun 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- EisnerAmper LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- ANEB
- Exchange
- OTC
- IPO date
- May 10, 2021
- Shares outstanding
- 41M, Feb 6, 2026
- Public float
- $15.06M, Dec 31, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1815974
- CUSIP
- 034569103
- ISIN
- US0345691036
- LEI
- 549300XYJQJDSQZ0AY81
- EIN
- 85-1170950
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Cunningham, Richard Anthony | Chief Executive Officer, Director | – |
| Kenneth C. Cundy | Chief Scientific Officer | – |
| Areta Kupchyk | Director | – |
| Joseph F. Lawler | Director | 12,000,000 |
| Kenneth Lin | Director | – |
| Nathaniel Calloway | Director | – |
| Bimal R. Shah | Director | – |
| Aron R. English | Director | 20,121,828 |
| Jason Aryeh | Director | – |
Employees
Headcount reported in annual reports
“As of June 30, 2025, we had two full-time employees and one part-time employee, none of whom were covered by collective bargaining agreements.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 2, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Feb 17, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Feb 6, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 24, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 10, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| May 5, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |